Midland Regional Hospital
Welcome,         Profile    Billing    Logout  
 5 Trials 
14 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Clarke, Gerard
NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

Recruiting
3
612
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
12/24
02/25
NCT05535946: ABTECT - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
06/26
FOCUS, NCT04951674: Dietary Fiber, Microbiota and Cognitive Function in Healthy Adults

Recruiting
N/A
150
Europe
High fiber diet, Control diet
University College Cork
Healthy
07/23
07/23
Move4Mood, NCT06398496: The Effects of Exercise on Gut Bacteria, Mood and Cognition in Depression

Recruiting
N/A
40
Europe
Aerobic Exercise, exercise, cardio, cardiorespiratory exercise
University College Cork
Depressive Disorder, Major
03/25
05/25
NMB, NCT05931536: The Relationship Between Diet, Cognition, Stress, and the Gut Microbiota

Recruiting
N/A
350
Europe
Dietary fibre
University College Cork
Healthy
07/24
07/24
NMB, NCT05931562: The Impact of Diet on the Gut-Microbiota-Brain Axis

Recruiting
N/A
200
Europe
Fermented Foods, High Fibre, Combined Diet, Control
University College Cork
Healthy
07/26
07/26
Hisabe, Takashi
NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

Recruiting
3
612
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
12/24
02/25
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
01/25
12/26
NCT05535946: ABTECT - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
06/26
Kirca, Murat
NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

Recruiting
3
612
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
12/24
02/25
NCT05535946: ABTECT - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
06/26
Kelly, Orlaith
NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

Recruiting
3
612
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
12/24
02/25
NCT05535946: ABTECT - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
06/26
NCT06275204: H. Pylori Screen-and-treat Study in a Population of Young Adults

Recruiting
N/A
6800
Europe, RoW
Bismuth-based quadruple therapy, Levofloxacin-based quadruple therapy, Standard triple therapy, Levofloxacin-based triple
University of Latvia, Clinical Hospital Center Rijeka, Clinical Hospital Centre Zagreb, Beacon Hospital, Wroclaw Medical University, Iuliu Hatieganu University of Medicine and Pharmacy, National Institute of Public Health, Slovenia
Gastric Cancer, H Pylori Infection, H Pylori Eradication, H-pylori
10/26
12/26

Download Options